Conversion from calcineurin inhibitor (CNI) based therapy to Sirolimus (SLR) is effective after steroid withdrawal (STW) in African American (AA) patients with late renal allograft dysfunction

被引：0
|
作者：
Singh, Pooja [1 ,2 ]
Kalra, Tamanna [1 ,2 ]
Fontanilla, John [1 ,2 ]
Gulati, Rakesh [1 ,2 ]
Burke, James, Jr. [1 ,2 ]
Wardrip, Jane [1 ,2 ]
Doria, Cataldo [1 ,2 ]
Francos, George [1 ,2 ]
机构：
[1] Thomas Jefferson Univ Hosp, Dept Med, Div Nephrol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ Hosp, Div Transplant Surg, Philadelphia, PA 19107 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2008年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：586 / 586
页数：1
相关论文
共 33 条
  • [21] Conversion to sirolimus from a calcineurin inhibitor based protocol does not worsen proteinuria or glomerular permeability to macromolecules in patients with chronic allograft nephropathy.
    Guasch, Antonio
    Barakat, Iyad
    Near, Mitzi
    Selvaraj, Sasi
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 441 - 441
  • [22] Conversion to Combined Mycophenolate Mofetil and Low-Dose Calcineurin Inhibitor Therapy for Renal Dysfunction in Liver Transplant Patients: Never Too Late?
    Susanne Beckebaum
    Vito R. Cicinnati
    Digestive Diseases and Sciences, 2011, 56 : 4 - 6
  • [23] Conversion to Combined Mycophenolate Mofetil and Low-Dose Calcineurin Inhibitor Therapy for Renal Dysfunction in Liver Transplant Patients: Never Too Late?
    Beckebaum, Susanne
    Cicinnati, Vito R.
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (01) : 4 - 6
  • [24] Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: Final results of the spare-the-nephron (STN) trial.
    Pearson, T. C.
    Mulgaonkar, S.
    Patel, A.
    Scandling, J.
    Shidban, H.
    Weir, M.
    Patel, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 213 - 213
  • [25] Outcome of calcineurin inhibitor (CNI) withdrawal and conversion to triple therapy with chronic basiliximab infusion, sirolimus (SRL) and enteric coated mycophenolic sodium (EC-MPS) in kidney recipients with biopsy proven moderate/Severe chronic allograft nephropathy (CAN) and graft dysfunction.
    Anil Kumar, Mysore S.
    Khan, Shahid M.
    Malat, Greory E.
    Culkin, Christine
    Sustento-Reodica, Nedjema
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 527 - 527
  • [26] Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients
    Fructuoso, A. Sanchez
    Millan, J. C. Ruiz San
    Calvo, N.
    Rodrigo, E.
    Moreno, M. A.
    Cotorruelo, J.
    Conesa, J.
    Gomez-Alamillo, C.
    Arias, M.
    Barrientos, A.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2148 - 2150
  • [27] Mechanisms of improvement in renal function after conversion to sirolimus (SRL) from a calcineurin-inhibitor (CI) regimen in patients with chronic transplant nephropathy (CTN).
    Barakat, IB
    Zayas, CF
    Guasch, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 365A - 365A
  • [28] Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study
    Budde, Klemens
    Rath, Thomas
    Sommerer, Claudia
    Haller, Hermann
    Reinke, Petra
    Witzke, Oliver
    Suwelack, Barbara
    Baeumer, Daniel
    May, Christoph
    Porstner, Martina
    Arns, Wolfgang
    CLINICAL NEPHROLOGY, 2015, 83 (01) : 11 - 21
  • [29] Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency
    Kamar, Nassim
    Frimat, Luc
    Blancho, Gilles
    Wolff, Philippe
    Delahousse, Michel
    Rostaing, Lionel
    TRANSPLANT INTERNATIONAL, 2007, 20 (02) : 128 - 134
  • [30] Everolimus (RAD)/Enteric-coated Mycophenolate Sodium (EC-MPS) therapy after Calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: Final outcomes of the ZEUS study
    Eisenberger, U.
    Pietruck, F.
    Klempnauer, J.
    Arns, W.
    Fehr, T.
    Sommerer, C.
    Reinke, P.
    Kramer, S.
    Budde, K.
    SWISS MEDICAL WEEKLY, 2008, 138 (47-48) : 5S - 5S
1234